Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics. It is grouped under the following drug class(es): Fluoroquinolones, Quinolones and Topoisomerase inhibitors. Its therapeutic use is listed as antibiotics and ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tequin, Gatiflo, Zymar and Zymaxid. Its PubChem CID is 5379.
Gatifloxacin
| CAS No | 112811-59-3 |
|---|---|
| Molecular Formula | C19H22FN3O4 |
| Molecular Weight | 375.4 g/mol |
| Synonyms | 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV.
The listed CAS number is 112811-59-3.
The listed molecular formula is C19H22FN3O4.
The listed molecular weight is 375.4 g/mol.
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid.
The source lists Tequin, Gatiflo, Zymar and Zymaxid.